Top

BMC Cancer

Published in:

Open Access 01-12-2016 | Research article

EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations

Authors: Jing Gao, Qingwei Meng, Yanbin Zhao, Xuesong Chen, Li Cai

Published in: BMC Cancer | Issue 1/2016

Abstract

Background

Non-small cell lung cancer (NSCLC) is one of the most aggressive types of cancer. However, resistance to cisplatin (CDDP) remains a major challenge in NSCLC treatment. The purpose of this study was to investigate the ability of EHD1 [Eps15 homology (EH) domain - containing protein 1] to confer CDDP resistance in NSCLC cells and to investigate mechanisms of this resistance.

Methods

The associations between EHD1 expression in NSCLC specimens and clinicopathological features, including prognosis, were assessed by immunohistochemistry (IHC). Using DNA microarrays, we performed a genome-wide analysis of cisplatin-resistant NSCLC cells to identify the involvement of the EHD1 gene in this resistance. We overexpressed and knocked down EHD1 in cell lines to investigate the effect of this gene on proliferation and apoptosis. A quantitative analytical method for assessing CDDP in cells was developed. High-performance liquid chromatography was used to measure the concentration of cisplatin in cells.

Results

The immunohistochemistry assay showed that adjuvant chemotherapy-treated NSCLC patients expressing EHD1 exhibited reduced OS compared with patients who did not express EHD1 (P = 0.01). Moreover, DNA microarrays indicated that the EHD1 gene was upregulated in CDDP- resistant NSCLC cells. The IC50 value of CDDP in cells that overexpressed EHD1 was 3.3-fold greater than that in the A549-control line, and the IC50 value of EHD1 knockdown cells was at least 5.2-fold lower than that of the control cells, as evidenced by a CCK-8 assay. We found that the percentage of early apoptotic cells was significantly decreased in A549-EHD1 cells, but the rates of early apoptosis were higher in the EHD1 knockdown cell line than in the A549/DDP control line, as indicated by a flow cytometry analysis. High-performance liquid chromatography (HPLC) showed that the total platinum level was lower in A549-EHD1 cells than in control cells, and the concentration of CDDP was higher in the EHD1 knockdown cells than in the A549/DDP control cells.

Conclusion

We conclude that EHD1 is required for tumour growth and that it is a regulator of CDDP accumulation and cytotoxicity. The selective knockdown of EHD1 in tumours offers a strategy for enhancing the efficacy of CDDP.

Available only for authorised users

Cao JZ, Song YM, Bi N, Shen J, Liu WY, Fan J, Sun GG, Tong T, He J, Shi YK, Zhang X, Lu N, He YH, Zhang HY, Ma KL, Luo XY, Lv L, Deng H, Cheng J, Zhu JD, Wang LH, Zhan QM. DNA methylation-mediated repression of miR-886-3p predicts poor outcome of human small cell lung cancer. Cancer Res. 2013;73:3326–35.CrossRefPubMed

Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.CrossRefPubMed

Schiller JH, Harrington D, Belani CP, Langer C., Sandler A, Krook J, Zhu J, Johnson DH. Comparison of four chemotherapy regimens for advanced non–small-cell lung cancer. N Engl J Med. 2002;346:92–8.CrossRefPubMed

Minn AJ, Rudin CM, Boise LH, Thompson CB. Expression of bcl-xL can confer a multidrug resistance phenotype. Blood. 1995;86:1903–10.PubMed

Simonian PL, Grillot DAM, Nunez G. Bcl-2 and BcL-XL can differentially block chemotherapy - induced cell death. Blood. 1997;90:1208–16.PubMed

Niedner H, Christen R, Lin X, Howell SB. Identification of genes that mediate sensitivity to cisplatin. Mol Pharmacol. 2001;60:1153–60. doi:10.1124/mol.60.6.1153.PubMed

Wu ZZ, Lu HP, Chao CCK. Identification and functional analysis of genes which confer resistance to cisplatin in tumor cells. Biochem Pharmacol. 2010;80:262–76.CrossRefPubMed

Zhang J, Naslavsky N, Caplan S. Rabs and EHDs: alternate modes for traffic control. Biosci Rep. 2012;32:17–23.CrossRefPubMed

Rapaport D, Auerbach W, Naslavsky N, Pasmanik-Chor M, Galperin E, Fein A, Caplan S, Joyner AL, Horowitz M. Recycling to the plasma membrane is delayed in EHD1 knockout mice. Traffic. 2006;7:52–60.CrossRefPubMed

10.

Cai B, Katafiasz D, Horejsi V, Naslavsky N. Pre-sorting endosomal transport of the GPI-anchored protein, CD59, is regulated by EHD1. Traffic. 2011;12:102–20.CrossRefPubMed

11.

Naslavsky N, Caplan S. EHD proteins: key conductors of endocytic transport. Trends Cell Biol. 2011;21:122–31.CrossRefPubMed

12.

Sharma M, Naslavsky N, Caplan S. A role for EHD4 in the regulation of early endosomal transport. Traffic. 2008;9:995–1018.CrossRefPubMedPubMedCentral

13.

Lu QL, Insinna C, Ott C, Stauffer J, Pintado PA, Rahajeng J, Baxa U, Walia V, Cuenca A, Hwang YS, Daar IO, Lopes S, Lippincott-Schwartz J, Jackson PK, Caplan S, Westlake CJ. Early steps in primary cilium assembly require EHD1/EHD3-dependent ciliary vesicle formation. Nat Cell Biol. 2015;17:228–40.CrossRefPubMedPubMedCentral

14.

Liang XJ, Shen DW, Garfield S, Gottesman MM. Mislocalization of membrane proteins associated with multidrug resistance in cisplatin -resistant cancer cell lines. Cancer Res. 2003;63:5909–16.PubMed

15.

Shen DW, Akiyama S, Schoenleinl P, Pastan I, Gottesman MM. Characterisation of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: cross-resistance and protein changes. Br J Cancer. 1995;71:676–83.CrossRefPubMedPubMedCentral

16.

Harrington CF, Le Pla RC, Jones GDD, Thomas AL, Farmer PB. Determination of cisplatin 1,2-intrastrand guanine-guanine DNA adducts in human leukocytes by high- performance liquid chromatography coupled to inductively coupled plasma mass spectrometry. Chem Res Toxicol. 2010;2(3):1313–21.CrossRef

17.

Naredi P, Heath DD, Enns RE, Howell SB. Cross-resistance between cisplatin and antimony in a human ovarian carcinoma cell line. Cancer Res. 1994;52:6464–8.

18.

Doherty GJ, McMahon HT. Mechanisms of endocytosis. Annu Rev Biochem. 2009;78:857–902.CrossRefPubMed

19.

Naslavsky N, Boehm M, Backlund PS, Caplan S. Rabenosyn-5 and EHD1 interact and sequentially regulate protein recycling to the plasma membrane. Mol Biol Cell. 2004;15:2410–22.CrossRefPubMedPubMedCentral

20.

Sharma M, Jovic M, Kieken F, Naslavsky N, Sorgen P, Caplan S. A model for the role of EHD1-containing membrane tubules in endocytic recycling. Commun Integr Biol. 2009;2:431–3.CrossRefPubMedPubMedCentral

21.

Chukkapalli S, Amessou M, Dekhil H, Dilly AK, Liu Q, Bandyopadhyay S, Thomas RD, Bejna A, Batist G, Kandouz M. Ehd3. Ehd3, a regulator of vesicular trafficking, is silenced in gliomas and functions as a tumor suppressor by controlling cell cycle arrest and apoptosis. Carcinogenesis. 2014;35:877–85.

Title: EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations
Authors: Jing Gao
Qingwei Meng
Yanbin Zhao
Xuesong Chen
Li Cai
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-016-2527-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2016

Racial differences in six major subtypes of melanoma: descriptive epidemiology

PRognostic factor of Early Death In phase II Trials or the end of ‘sufficient life expectancy’ as an inclusion criterion? (PREDIT model)

Combined chemoradiation of cisplatin versus carboplatin in cervical carcinoma: a single institution experience from Thailand

The effect of a germline mutation in the APC gene on β-catenin in human embryonic stem cells

Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases

Incidence and risk of hypertension in patients newly treated for multiple myeloma: a retrospective cohort study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer